CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Rating of “Moderate Buy” by Brokerages

CeriBell, Inc. (NASDAQ:CBLL) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $22.20.

CBLL has been the topic of several recent research reports. Canaccord Genuity Group lowered their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Finally, BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th.

CeriBell Price Performance

NASDAQ CBLL opened at $16.30 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 9.35. The stock’s fifty day moving average price is $19.11 and its 200 day moving average price is $18.88. CeriBell has a 1 year low of $10.85 and a 1 year high of $24.33. The company has a market cap of $618.42 million, a price-to-earnings ratio of -10.00 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. As a group, equities research analysts forecast that CeriBell will post -1.68 earnings per share for the current year.

Insider Activity

In other news, VP David Foehr sold 4,560 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total transaction of $81,168.00. Following the sale, the vice president directly owned 17,550 shares of the company’s stock, valued at $312,390. This represents a 20.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Josef Parvizi sold 16,714 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $20.27, for a total transaction of $338,792.78. Following the sale, the director directly owned 722,652 shares in the company, valued at approximately $14,648,156.04. The trade was a 2.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 175,119 shares of company stock valued at $3,310,772. Insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

A number of hedge funds have recently bought and sold shares of CBLL. Russell Investments Group Ltd. increased its holdings in shares of CeriBell by 41.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after buying an additional 854 shares during the last quarter. Sei Investments Co. boosted its position in CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after buying an additional 1,125 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the last quarter. Deutsche Bank AG lifted its position in shares of CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of CeriBell during the 1st quarter worth $27,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.